famotidine has been researched along with Xerostomia in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Xerostomia: Decreased salivary flow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasama, T | 1 |
| Shiozawa, F | 1 |
| Isozaki, T | 1 |
| Matsunawa, M | 1 |
| Wakabayashi, K | 1 |
| Odai, T | 1 |
| Yajima, N | 1 |
| Miwa, Y | 1 |
| Negishi, M | 1 |
| Ide, H | 1 |
1 trial available for famotidine and Xerostomia
| Article | Year |
|---|---|
Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome.
Topics: Aged; Aged, 80 and over; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ni | 2008 |